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Background: Preventive therapy is a risk reduction option for women who have an increased risk of breast cancer.
The effectiveness of preventive therapy to reduce breast cancer incidence depends on adequate levels of uptake and ad-
herence to therapy. We aimed to systematically review articles reporting uptake and adherence to therapeutic agents to
prevent breast cancer among women at increased risk, and identify the psychological, clinical and demographic factors
affecting these outcomes.
Design: Searches were carried out in PubMed, CINAHL, EMBASE and PsychInfo, yielding 3851 unique articles. Title,
abstract and full text screening left 53 articles, and a further 4 studies were identiﬁed from reference lists, giving a total of
57. This review was prospectively registered with PROSPERO (CRD42014014957).
Results: Twenty-four articles reporting 26 studies of uptake in 21 423 women were included in a meta-analysis. The
pooled uptake estimate was 16.3% [95% conﬁdence interval (CI) 13.6–19.0], with high heterogeneity (I2 = 98.9%,
P < 0.001). Uptake was unaffected by study location or agent, but was signiﬁcantly higher in trials [25.2% (95% CI 18.3–
32.2)] than in non-trial settings [8.7% (95% CI 6.8–10.9)] (P < 0.001). Factors associated with higher uptake included
having an abnormal biopsy, a physician recommendation, higher objective risk, fewer side-effect or trial concerns, and
older age. Adherence (day-to-day use or persistence) over the ﬁrst year was adequate. However, only one study reported
a persistence of ≥80% by 5 years. Factors associated with lower adherence included allocation to tamoxifen (versus
placebo or raloxifene), depression, smoking and older age. Risk of breast cancer was discussed in all qualitative studies.
Conclusion: Uptake of therapeutic agents for the prevention of breast cancer is low, and long-term persistence is often
insufﬁcient for women to experience the full preventive effect. Uptake is higher in trials, suggesting further work should
focus on implementing preventive therapy within routine care.
Key words: preventive therapy, chemoprevention, decision-making, adherence, uptake, medication
introduction
Breast cancer is the most commonly diagnosed cancer in women,
with an estimated 1.67 million new cases diagnosed worldwide in
2012 [1]. Over 500 000 deaths are recorded each year, making it
the leading cause of cancer death in women [1]. It is expected
that one in eight US women will be diagnosed with the disease
in their lifetime [2]. A decline in breast cancer mortality has
been observed over the last 40 years [3, 4], although incidence
continues to rise [5, 6], particularly in developing countries [7].
A number of factors have been associated with an increased risk
of developing breast cancer [8], including family history which
accounts for ∼5%–10% of all breast cancers.
Preventive therapy is a risk reduction option for women who
have an increased risk of breast cancer. Selective Estrogen
Receptor Modulators (SERMs) have been extensively tested, and
trials of alternative agents are ongoing. A meta-analysis of 10-
year individual-level data from nine randomized SERM trials
demonstrated a 38% reduction in overall breast cancer incidence
and a 51% reduction in estrogen receptor positive (ER+) tumours
[9]. The preventive effect of tamoxifen can last at least 20 years
[10]. Women taking SERMs have more venous thromboembolic
events and more endometrial cancers [9]. Menopausal symptoms
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such as hot ﬂashes and vaginal dryness are also more common
among women taking SERMs, which can affect tolerability [11].
The effectiveness of preventive therapy to reduce breast cancer
incidence at a population level depends on adequate levels of
uptake and adherence to therapy. The discovery and testing of new
agents also relies on acceptability to the population. An estimated
2 million US women and 500 000 UK women have favourable
cost–beneﬁt proﬁles for the prophylactic use of tamoxifen [12, 13].
However, a meta-analysis of ﬁve studies reporting uptake data in
non-trial settings found a mean uptake of just 14.8% among
women offered the opportunity to take preventive therapy [14].
Trial data were not included in this review. Independent studies
and narrative reviews have also raised concern about the low levels
of long-term adherence to preventive therapy [11, 15, 16], but no
systematic synthesis has been done.
To make recommendations for future research and clinical
practice, this review aims to synthesize the available quantitative
data on uptake of preventive therapy and adherence among
women who have an increased risk of breast cancer in either
trial or non-trial settings. To aid the development of behavioural
interventions, we aimed to identify the sociodemographic, clin-
ical and psychological factors associated with uptake and adher-
ence. Qualitative studies were also included in this investigation
to supplement our understanding of women’s decision-making
in this context.
methods
search strategy
We searched for quantitative articles reporting uptake and ad-
herence to medications used for the purpose of preventing
primary breast cancer, and quantitative and qualitative articles
reporting factors affecting these decisions. Adherence included
either adequate day-to-day use of the medication or persistence
with it over time. In November 2014, separate searches were
carried out in PubMed, CINAHL, EMBASE and PsychInfo (see
supplementary Appendix S1, available at Annals of Oncology
online for example search terms). The review was prospectively
registered on the PROSPERO database [17] (registration number:
CRD42014014957). PRISMA guidelines were followed throughout
[18] (supplementary Appendix S2, available at Annals of Oncology
online).
article selection
The inclusion criteria were peer-reviewed studies: in English
language; including women aged 18 years or older; reporting
quantitative or qualitative data; including at least one aspect of
medication use (uptake, day-to-day adherence with prescription
guidelines and/or persistence with the medication over time);
and using or testing the agent for the purpose of breast cancer
prevention. Qualitative studies had to investigate eligible
women’s perceptions of preventive therapy and explanations for
their decisions associated with chemoprevention. The exclusion
criteria were studies including women affected by breast cancer
(including ductal carcinoma in situ), agents where the primary
purpose was not breast cancer prevention, hypothetical rates of
adherence, men only, clinician perspectives, non-peer-reviewed
studies, conference abstracts, reviews, interventions not involving
oral agents and commentaries and letters not including empirical
data. No restriction was placed on publication dates or study
design.
After removing duplicates, two authors (SGS, AF) used the
inclusion and exclusion criteria to review half of the titles and
abstracts each. The same authors checked the excluded articles
of the other person to ensure sensitivity. A similar process was
undertaken for the full texts. The remaining article’s reference
lists were examined to identify studies not included in our
search. The articles included in the meta-analysis were decided
by mutual discussion (SGS, IS).
data extraction
Data were extracted by one author using electronic database
software (SGS). Guided by the Cochrane Handbook for
Systematic Reviews Handbook, two authors (SGS, IS) agreed on
the appropriate variables to be extracted [19] and this was
piloted by SGS. The variables extracted included study authors,
date, location, design, analysis (qualitative), context (trial/non-
trial), sample size, sample age, uptake levels, adherence levels,
adherence type (day-to-day/persistence), factors tested for an as-
sociation with adherence and qualitative themes.
quality assessment
The Mixed Methods Appraisal Tool (MMAT) can be used to
assess study quality in mixed study reviews [20]. The MMAT is
reliable [21], and has been used in reviews of decision-making
in the context of cancer [22, 23]. Each study is screened using
two items related to the quality of the objectives, and the extent
to which the data address the objectives. Study designs are clas-
siﬁed as: (i) qualitative; (ii) quantitative randomized, controlled
trials; (iii) quantitative non-randomized; (iv) quantitative de-
scriptive; and (v) mixed methods. Study designs i–iv each have
four of their own quality assessment items. Mixed methods
studies are rated using three items, and then both sets of items
for the two types of data reported (e.g. quantitative non-rando-
mized and qualitative). All items are rated as ‘yes’, ‘no’ or ‘can’t
tell’, with one point awarded for each ‘yes’ response. Scores
range from 0–4, with mixed method studies only able to score as
highly as their lowest score for each study design. One researcher
(SGS) assessed the quality of all included articles using the
MMAT, and 20% of these were randomly selected and checked
by a second researcher (AF) to ensure agreement. Discrepancies
were resolved through discussion. MMAT scores were assessed
at the study level and so were not necessarily associated with the
quality of uptake and adherence data. To overcome this limita-
tion, we created a single subjective evaluation assessing the
extent to which the article contributed to our review.
analysis
Random effect meta-analysis was used to allow for heterogeneity
across uptake studies. Data were analysed in STATA 13.1 using
the ‘metaprop’ command. Study heterogeneity was assessed
with Q statistics and I2 estimations [24]. Results are plotted as a
proportion (%) of women who have taken up preventive therapy
with corresponding 95% conﬁdence intervals and all P-values
are two-sided. A quantitative synthesis of the adherence data
was not possible due to differences in the data collection
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measure (e.g. pill count, clinical assessment, Medication Events
Monitoring Systems) and type of adherence data collected (e.g.
day-to-day, persistence or both). Therefore, a narrative synthesis
describing these data was done. A narrative synthesis of the
qualitative data was also carried out.
results
The initial search yielded 4743 articles, of which 3850 remained
after removing duplicates (Figure 1). Title screening led to 3345
exclusions, and a further 320 articles were removed after review-
ing the remaining abstracts. One hundred and eighty-ﬁve full-
text articles were assessed and 53 met inclusion/exclusion
criteria. The reference lists of the remaining 53 articles were
searched, and a further 4 manuscripts were identiﬁed. A total of
57 articles are included in the review.
characteristics of included studies
Thirty-one articles reported uptake (Table 1) and 23 reported
adherence (Table 2). Seventeen papers (30%) scored the
maximum of 4/4 on the MMAT, the majority of which were
non-randomized quantitative studies [26, 27, 35, 39, 41, 44, 47,
55, 56, 59, 61–64, 73, 75, 76]. Four studies (7%) met only one of
the four assessment criteria [31, 37, 40, 67], all of which were
randomized quantitative studies. Only three studies (5%) were
given the highest rating of 4/4 using our subjective assessment
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– Letter, commentary, editorial with no
empirical data (n = 45)
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– No adherence data reported (n = 43)
– Breast cancer survivors only (n = 1)
– Not oral agent taken for breast cancer
prevention (n = 10)
– Book chapter (n = 1)
– Review (n = 3) 
Figure 1. Flow diagram of search strategy.
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Table 1. Characteristics of articles reporting uptake levels of breast cancer preventive therapy
Study Country Design Setting Agent n Age, years Uptake
Altschuler and Somkin [25] USA Mixed STAR trial Tamoxifen; raloxifene 51 40–49 (2%); 50–59 (29%);
60–69 (35%); 70–79
(31%); >80 (2%)
54.9%
Bober et al. [26] USA Non-randomized Non-trial; STAR Tamoxifen; raloxifene 129 Mean, 52; SD, 8 25.6% (tamoxifen); 25.6%
(STAR)
Collins et al. [27] Australia Non-randomized kConFab Tamoxifen 325 Median, 37, range 18–78 0.3% (tamoxifen); 2.8%
(Trial)
Donnelly et al. [28] UK Mixed Non-trial Tamoxifen 1279 Median, 42 10.6%
Evans et al. [29] UK Non-randomized IBIS1, IBIS2 Tamoxifen; anastrozole 2278; 1264 Not reported 12.0% (IBIS1); 8.1% (IBIS2)
Evans et al. [30] UK Non-randomized IBIS1; LHRH Tamoxifen; raloxifene 278; 142 Not reported 11.5% (IBIS1); 9.9%
(LHRH)
Fagerlin et al. [31] USA Randomized Non-trial Tamoxifen; raloxifene 482 Mean, 62; SD, 5 0.4%
Goldenberg et al. [32] USA Non-randomized Non-trial Tamoxifen 99 Mean, 46 11.1%
Houlihan et al. [33] USA Non-randomized STAR trial Tamoxifen; raloxifene 242 Not described 33.5%
Juraskova et al. [34] International Randomized IBIS2 Anastrozole 290 Mean, 59 46.4%
Yeomans Kinney et al. [35] USA Non-randomized NSABP P-1 Tamoxifen 89 Mean, 59 43.8%
Yeomans-Kinney et al. [36] USA Non-randomized NSABP P-1 Tamoxifen 175 Mean, 55; SD, 10 50.9%
Korfage et al. [37] USA Randomized Non-trial Tamoxifen; raloxifene 1012 Mean, 62; SD, 6 0.3%
Kwong et al. [38] China Non-randomized Non-trial Tamoxifen; raloxifene 26 Mean, 43; SD, 12 0%
Loehberg et al. [39] Germany Non-randomized IBIS2 Anastrozole 2524 Mean 60; SD, 6 1.5%
Matloff et al. [40] USA Randomized STAR trial Tamoxifen; raloxifene 48 Mean, 49 0%
Metcalfe et al. [41] International Non-randomized Non-trial Tamoxifen; raloxifene 2677 Mean 46 5.5% (tamoxifen); 2.9%
(raloxifene)
Metcalfe et al. [42] International Non-randomized Non-trial Tamoxifen; raloxifene 81 Mean, 45 12.3% (tamoxifen); 9.9%
(raloxifene)
Ozanne et al. [43] USA Randomized Non-trial Tamoxifen; raloxifene 30 Control: mean, 44; SD, 10
versus Intervention:
mean, 45; SD, 11
2/26 7.7%
Phillips et al. [44] International Non-randomized kConFab Tamoxifen 142 Mean, 41 0.7%
Port et al. [45] USA Non-randomized Non-trial Tamoxifen 43 Mean, 53 4.7%
Pujol et al. [46] France Non-randomized LIBER Letrozole 237 40–49 (36%), 50–69 (64%) 14.0%
Razzaboni et al. [47] Italy Non-randomized IBIS II Anastrozole 471 Mean, 59 (SD, 6) 29.1%
Rondanina et al. [48] Italy Non-randomized HOT study Tamoxifen 1457 Mean, 56 (SD, 5) 34.0%
Taylor and Taguchi [49] Canada Non-randomized Non-trial Tamoxifen; raloxifene 88 40–49 (12%), 50–59 (20%),
60–69 (37%), 70–80
(30%)
6.7%
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[62, 63, 47], and ﬁve (9%) scored just 1/4 [57, 66, 71, 74, 77].
The mean quality score using the MMAT was 3.1 out of 4 com-
pared with 2.5 out of 4 using the subjective assessment (supple-
mentary Tables S1–S3, available at Annals of Oncology online).
Using MMAT categories, 34 studies used a non-randomized
quantitative design [26, 27, 29, 30, 32, 33, 35, 36, 38, 39, 41, 42,
44–56, 59, 60–65, 72, 74], 16 used a randomized quantitative
design [31, 34, 37, 40, 43, 57, 58, 66–71, 73, 75, 76], 5 studies
were qualitative [77–81] and 2 were mixed-methods [25, 28].
Among the qualitative and mixed methods studies, ﬁve reported
interview data [25, 28, 77, 79, 81] and two reported focus group
data [78, 80]. The majority of quantitative studies (n = 36) were
from trials [25, 29, 30, 33–36, 39, 40, 46–48, 51, 56–77], with 20
studies reporting non-trial data from clinics, cohorts and
national surveys [27, 28, 31, 32, 37, 38, 41–45, 49, 50, 52–55, 78,
80, 81], and 2 studies included both trial and non-trial data [26,
79]. The majority of studies (n = 50) reported data on SERMs,
with the remaining studies using aromatase inhibitors (AIs)
(n = 6) [29, 34, 39, 46, 47, 56], aspirin [66], lovastatin [74] and
luteinizing-hormone-releasing hormone (LHRH) [30].
The sample size of the quantitative studies ranged from 30
[43, 74] to 19 471 [75, 76], and the qualitative studies ranged
from 2 [77] to 51 [25]. The studies were from a range of coun-
tries, including 30 from the USA [25, 26, 31–33, 35–37, 40, 43,
45, 50–55, 59, 60, 62, 64, 66, 71, 74, 75–78, 80, 81], 8 from the
UK [28–30, 61, 65, 68–70], 3 from Italy [47, 48, 72], 3 from
Canada [49, 53, 79] and 1 from each of Germany [39], Australia
[27], China [38], France [46] and Finland [67]. Eight studies
were international [34, 41, 42, 44, 56–58, 72]. Age was variably
reported, but the lowest recorded was a median of 39 years [27]
and the highest was a mean of 67 years [62].
uptake of breast cancer preventive therapy
For the meta-analysis, 24 articles reporting 26 studies of uptake
in 21 423 women were included. Seven articles reporting uptake
were not included because more complete or similar data were
available in another study [27, 31, 35, 36, 42, 44, 50]. Uptake
ranged from 0% [38, 40] to 54.9% [25]. The pooled uptake esti-
mate was 16.3% (95% CI 13.6–19.0), with high heterogeneity
(I2 = 98.9%, P < 0.001) (Figure 2). Uptake was higher in trials
[25.2% (95% CI 18.3–32.2)] than in non-trial settings [8.7%
(95% CI 6.8–10.9)], and this difference was statistically signiﬁ-
cant (P < 0.001). Uptake was unaffected by agent and study loca-
tion (supplementary Figures S1 and S2, available at Annals of
Oncology online).
Fourteen of the uptake studies tested at least one predictor of
uptake within the study (Table 3). Clinical factors associated
with higher uptake in more than one study included having an
abnormal breast biopsy [26, 54] and receiving a physician rec-
ommendation [26, 36]. Higher clinically assessed risk was asso-
ciated with higher uptake in two studies [28, 54], but this effect
was not consistent [36, 48]. Clinical factors reaching statistical
signiﬁcance in one study included having all questions answered
by a physician, perceiving that the clinician supported their
understanding of preventive therapy [48], and not having a
BRCA mutation [28]. Previous experience of hot ﬂashes was
associated with lower uptake in one study [51], but there was no
association in another [36]. There was no association between
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Table 2. Characteristics of articles reporting adherence data on breast cancer preventive therapy
Authors Country Design Setting Agent n Age (years) Measure Follow-up time (years) Day-to-day
adherence
Persistence
Cheung et al. [56] International Non-randomized MAP.3 Exemestane 239 Median, 61; IQR, 59–65 Pill count 2 Median: 97% –
Cuzick and Edwards
[57]
International Randomized IBIS-1 Tamoxifen 4303 Not described Pill count 1, 2, 4 – 90%; 83%; 74%
Cuzick et al. [58] International Randomized IBIS-1 Tamoxifen 7154 Mean, 51 Pill count 5 – 67.9%
Day et al. [59] USA Non-randomized NSABP P-1 Tamoxifen 11 064 Mean, 54; SD = 9 Clinic visit 3 – 80.8%
Day et al. [60] USA Non-randomized NSABP P-1 Tamoxifen 11 064 Mean, 54; SD = 9 Clinic visit 3 – 69.1%
Fallowfield et al. [61] UK Non-randomized IBIS1;
TAMOPLAC
Tamoxifen 488 Median, 46 Self-report 5 – 61.8%
Juraskova et al. [34] International Randomized IBIS2 Anastrozole 212 Mean, 59 Self-report 3 months – 88.2%
Klepin et al. [62] USA Non-randomized STAR trial Tamoxife;
raloxifene
1331 Mean, 67; SD, 4 Pill count Unclear, probably 2 86.3% –
Land et al. [63] USA Non-randomized NSABP P-1 Tamoxifen 11 064 ≥60 (30%) Clinic visit 1 and 36 months 91%; 79%a –
Land et al. [64] USA Non-randomized STAR trial Tamoxife;
raloxifene
1983 35–49 (10%), 50–59: (49%);
60–69 (31%); 70+ (10%)
Clinic visit 5 – Mean: 3 years
Maurice et al. [65] UK Non-randomized IBIS1 Tamoxifen 82 Not described MEMS Adherence, 6 months;
Persistence 5 years
Median % days
correct dose:
93.2–95.2
79.3%
McTiernan et al. [66] USA Randomized Trial Aspirin 143 Mean, 60; SD, 6 Pill count 6 months 87% –
Palva et al. [67] Finland Randomized IBIS1 Tamoxifen 96 Placebo: mean, 50; SD, 8;
Tamoxifen: mean, 51; SD, 8
Not reported 5 – 66.7%
Powles et al. [68] UK Randomized Pilot Tamoxifen 200 Tamoxifen: mean, 48; Placebo:
mean, 49
Self-report Months 3, 6, 9, 12 – 91.5%; 88.0%;
85.5%; 84.0%
Powles et al. [69] UK Randomized Royal Marsden Tamoxifen 2012 Median, 48 Self-report 5 – 80.8%
Powles et al. [70] UK Randomized Royal Marsden Tamoxifen 2471 Median, 47 Self-report 5 – 64.5%
Razzaboni et al. [47] Italy Non-randomized IBIS II Anastrozole 471 Mean, 59; SD, 6 Pill count 6 months, years 1, 2, 3 – 78.1%; 61.3%;
41.6%; 13.9%
Signori et al. [71] USA Randomized Pilot Raloxifene;
omega-3
fatty acids
46 Mean, 56–58 Pill count 1 96% –
Veronesi et al. [72] Italy Non-randomized ITPS Tamoxifen 201 Median, 53 Clinic visit 5 – 73.3%
Veronesi et al. [73] International Randomized ITPS Tamoxifen 3037 Median, 51 Clinic visit 1, 2, 3, 4, 5 – 86.1%; 80.1%;
76.2%;
74.2%; 73.7%
Vinayak et al. [74] USA Non-randomized Trial Lovastatin 30 Median, 45 Pill count 6 months – 86.7%
Vogel et al. [75] USA Randomized STAR trial Tamoxife;
raloxifene
19 471 Mean, 59; SD, 7 Not reported 4 – 68.3–71.5%
Vogel et al. [76] USA Randomized STAR trial Tamoxife;
raloxifene
19 471 Mean, 59; SD, 7 Not reported 5 – 61.1–72.6%
RCT-SS, Randomized, controlled trial substudy.
aReports a combined adherence and persistence measure; ITPS, Italian Tamoxifen Prevention Study.
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uptake and other clinical factors including the number of family
members diagnosed [36, 47, 54], experiencing a breast biopsy
[26, 54], previous hysterectomy [36, 51, 54] and menopausal
status [51, 54].
Lower uptake was consistently observed in women concerned
about contradictions with estrogen [36, 51]. Greater concern
about side-effects was associated with lower uptake in two
studies [26, 51], although no relationship was found in another
[35]. Statistically signiﬁcant patient factors implicated in only
one study included intrusive thinking [26], perceived vulnerabil-
ity [26], worry about breast cancer [48], concern at the experi-
mental nature of trials [51], personal desire to participate in a
trial [33], perceived value of trials [33], perceived inconvenience
of the trial [33], the frequency of clinic visits needed [51] and
alcohol consumption [48]. There was mixed or no evidence for
several other patient factors (Table 3).
No demographic factors were associated with uptake in more
than one study. Country of residence was associated with uptake
in a single study [41], with lower uptake in France, Italy,
Holland and Norway. There was inconsistent or no evidence for
age [28, 36, 47, 48, 51, 54], race [36], education [36, 47, 48, 51],
income [51], employment status [35], insurance [36, 51], parity
[54] and cost [35, 36, 51].
adherence to breast cancer preventive therapy
All adherence studies were from trial data (Table 2). Studies in-
vestigating adherence mainly reported data on persistence
(n = 18) [34, 47, 57–61, 64, 65, 67–70, 72–76]. Four reported
data on day-to-day adherence [56, 65, 66, 71], and two used a
hybrid measure of day-to-day adherence and persistence [62,
63]. Adherence measurement varied. Eight studies reported pill
count data [47, 56–58, 62, 66, 71, 74], six noted adherence
during a clinical visit [59, 60, 63, 64, 72, 73], ﬁve included self-
report data [34, 61, 68–70], one used Medication Even
Monitoring Systems (MEMS) [65] and three did not report how
adherence was measured [67, 75, 76]. Eight studies reported
Study Uptake % (95% Cl)
10.7 (7.3–15.1)
7.7 (0.9–25.1)
0.3 (0–1.2)
25.6 (18.3–34.0)
4.7 (0.6–15.8)
8.4 (7.0–10.0)
0.8 (0.6–1.0)
6.8 (2.5–14.3)
11.1 (5.7–19.0)
31.3 (18.7–46.3)
10.6 (9.0–12.5)
41.6 (33.3–50.3)
0 (0–5.0)
8.7 (6.6–10.9)
34.0 (31.6–36.5)
25.6 (18.3–34.0)
33.5 (27.6–39.8)
12.0 (10.7–13.4)
8.1 (6.7–9.8)
29.1 (25.0–33.4)
46.4 (37.0–56.1)
14.0 (11.2–17.3)
1.5 (0.3–4.3)
9.9 (5.5–16.0)
54.9 (40.3–68.9)
45.3 (38.7–51.9)
0 (0.7–4.0)
25.2 (18.3–32.2)
16.3 (13.6–19.0)
Clinic
Metcalfe (2007)
Ozanne (2007)
Korfage (2013)
Bober (2004)
Port (2001)
Metcalfe (2008)
Waters (2012)
Taylor (2005)
Goldenberg (2007)
Rahman (2009)
Donnelly (2014)
Tchou (2004)
Kwong (2010)
Subtotal (I2 = 97.2%, P < 0.001)
Trial
Rondanina (2008)
Bober (2004)
Houlihan (2010)
Evans (2010)
Evans (2nd uptake) (2010)
Razzaboni (2013)
Juraskova (2014)
Pujol (2012)
Loehberg (2010)
Evans (2001)
Altschuler (2005)
Yeomans-Kinney (1995)
Matloff (2006)
Subtotal (I2 = 98.6%, P < 0.001)
Overall (I2 = 98.9%, P < 0.001)
0
Proportion
68.9
Figure 2. Meta-analysis of individual-level data for preventive therapy uptake by setting.
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Table 3. Summary of factors affecting uptake of breast cancer preventive therapy
Bober et al.
[26]
Donnelly
et al. [28]
Evans
et al.
[29]
Goldenberg
et al. [32]
Houlihan
et al. [33]
Yeomans
Kinney
et al. [35]
Yeomans-
Kinney
et al. [36]
Metcalfe
et al. [41]
Ozanne
et al. [43]
Razzaboni
et al. [47]
Rondanina
et al. [48]
Yeomans-
Kinney
et al. [51]
Metcalfe
et al. [53]
Tchou
et al. [54]
Clinical factors
Family member diagnosed – – –
First-degree relative diagnosed –
First-degree relative died –
History breast biopsy – –
Abnormal breast biopsy ✓ ✓
Family history of stroke –
Family history of cataracts –
Regular physician –
Physician recommendation ✓✓ ✓✓
Physician helped me understand ✓✓
Physician answered all my
questions
✓
Having annual physical –
Objective risk ✓ – – ✓
No BRCA mutation ✓
Menopausal status – –
Hysterectomy – – –
HRT/estrogen usea X ✓
Experience of hot flashes – ✓
Patient factors
Concerned about side-effectsb ✓ – ✓✓
Concerned that estrogen
contraindicated
✓✓ ✓✓
Believe that medication will not
prevent cancer
✓ –
Intrusive thinking ✓
Depression – –
Anxiety –
Life orientation –
Autonomy –
Knowledge of breast cancer –
Perceived risk (not described) –
Perceived risk (vulnerability) ✓
Perceived risk (absolute) –
Perceived risk (relative) ✓ –
Perceived risk (numerical) –
Worry about breast cancer ✓✓
Peace of mind –
Concern about possibility of
placebo
– ✓ ✓✓

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Experimental nature of trial ✓
Perceived expertise of clinician –
Personal desire to participate ✓✓
Perceived value of trial ✓✓
Perceived inconvenience of trial ✓✓
Need to take a pill every day –
Frequency of clinic visits ✓
Travel time to clinic –
Body mass index –
Smoking –
Alcohol consumption (low) ✓✓
Physical activity –
Illegal drug use –
Prior use of screening –
Significant others reassured – ✓
Self-reported health –
Demographic factors
Older age ✓ – – ✓ X ✓
Race –
Country ✓
Marital status – – –
Education – – – –
Income –
Employment –
Insurance – –
Cost – – ✓✓
Parity –
Notes: –, tested, but not statistically significant; ✓, tested in univariable analyses, and significant; ✓✓, tested multivariable, and significant; X, significant in opposite of hypothesized direction.
aRondanina et al. [48] purposively sampled women who were currently taking or considering HRT for menopausal symptoms.
bYeomans-Kinney et al. [51] tested multiple different concerns about side-effects, the results of which were mixed.
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data from a 5-year follow-up [58, 61, 64, 65, 67, 69, 70, 72, 73,
76], and the shortest end-point was 3 months [34].
Overall, studies suggested day-to-day adherence to preventive
therapy was high, although all data were recorded within 2 years
of initiating therapy. Day-to-day adherence was particularly
high at 2-year follow-up in the MAP.3 exemestane trial (median,
97%) [56] and in a pilot trial of raloxifene with omega-3 followed
up for 1 year (96%) [71]. A study using MEMS also suggested
high rates of day-to-day adherence, at least in the ﬁrst 6 months
of therapy [65]. High rates of day-to-day adherence were reported
over a 6-month period in an aspirin trial (87%) [66]. The two
studies combining day-to-day adherence and persistence data
reported high rates, although this was likely to decline over time
[63]. One study only enrolled women who were adherent at base-
line, which could bias subsequent reports [62].
Among studies reporting 5-year follow-up data, persistence
ranged from 61.1% in the tamoxifen arm of the STAR trial [76]
to 80.8% in both arms of the Royal Marsden trial [69]. However,
a lower estimate of persistence (64.5%) in the Royal Marsden
trial was reported elsewhere [70]. Several studies indicated ad-
equate short-term persistence, which declined over time [57, 68,
73]. Italian data from the IBIS II Anastrozole trial reported a
sharp decline in persistence from 78.1% at 6 months to 61.3%,
41.6% and 13.9% in years 1, 2 and 3 [47].
Eleven studies investigating either day-to-day adherence
or persistence tested at least one predictor (Table 4). The most
important clinical factor appeared to be the agent used. Five
studies reported lower persistence to tamoxifen compared with
placebo [61, 69, 70] and raloxifene [64, 67]. Two studies re-
ported lower day-to-day adherence to tamoxifen compared with
placebo [63] and raloxifene [62]. One study showed comparable
persistence between tamoxifen and placebo [68], possibly due to
low statistical power. Day-to-day adherence was similar between
groups in a trial evaluating the effect of raloxifene versus
placebo and versus omega-3 fatty acids [71]. Higher objective
risk was associated with greater day-to-day adherence in one
large study [63], although a smaller subsample of the IBIS 1 trial
did not observe this effect [65]. Women with fewer depressive
symptoms were more persistent in two studies [59, 62], but no
effect was found in another [65]. There was mixed evidence for
the relationship between persistence and use of other medica-
tions [62, 65]. There was no evidence for the remaining clinical
factors (Table 4).
Non-smoking status was linked with higher day-to-day adher-
ence in two studies [63, 65]. One study suggested participants
who expected to be on therapy for longer were more adherent
[62]. The same study also demonstrated greater day-to-day adher-
ence among those with higher verbal memory, although multiple
other cognitive domains were tested which showed no effect [62].
There was no evidence for a relationship between adherence and
alcohol consumption [63], overweight [63] and physical activity
[63]. No demographic factor was consistently associated with ad-
herence, although two large studies suggested younger age was
linked with higher day-to-day adherence [62, 63], and one sug-
gested higher levels among the more educated [63]. There was no
evidence of other socioeconomic disparities, as assessed by ethni-
city [62, 63], employment [63] or income [63]. There was also no
relationship between day-to-day adherence and living alone [63],
marital status [65] or parity [65].
A relationship between side-effects and adherence was sug-
gested by reports of lower persistence among women taking
tamoxifen compared with placebo and raloxifene [61–64, 67, 69,
70]. However, the quality of side-effect assessment was poor.
The primary tool for assessment was ‘off-therapy forms’ (OTFs)
provided only to women who did not persist with the medica-
tion. These data are likely to be subject to attribution bias. Seven
tamoxifen studies used OTFs to document the proportion of
women who attributed their drop-outs to side-effects [59, 60,
63, 67–70] and one anastrozole trial used an OTF [47]. Data
from three placebo-controlled trials reported a higher propor-
tion of side-effect-related drop-outs among women taking tam-
oxifen [60, 67, 70], although almost half of the women stopping
prematurely attributed their decision to non-medical factors
[60, 70].
qualitative data on breast cancer preventive therapy
decision-making
The characteristics of the qualitative studies are shown in
Table 5 and the extracted themes are presented in Table 6. All
seven qualitative studies included were related to women’s atti-
tude towards tamoxifen or raloxifene, and their decision to initi-
ate preventive therapy. All studies discussed at least one aspect
of breast cancer risk. Five studies reported that women with a
heightened perceived personal risk were more likely to use pre-
ventive therapy [25, 78–81], with low perceived risk resulting
from a sense of wellness [78] or lack of symptoms [81]. Taking
preventive therapy was considered to be a daily reminder of
one’s risk [28], which some women preferred to deny [79] or
seek alternative strategies [80]. A Canadian study noted unreal-
istic views about prevention among some women, with risk-
reduction expectations ranging from 50% to 100% [79]. Three
studies reported that concerns about side-effects were a deter-
rent to uptake [25, 28, 79]. One diverse focus group study noted
a low awareness of preventive therapy [78], which may be as
a result of a lack of information about the topic [79] and
poor patient–provider communication [78]. Two other studies
reported a low level of understanding regarding the causes of
breast cancer [78, 81]. The use of medication for prevention was
considered to be an important topic [81], with women reporting
concerns about drug interactions [78], the ‘unnatural’ nature of
medications [78, 79, 81] and worries that HRT would be contra-
indicated [79, 25]. One high-quality study reported women were
reluctant to use tamoxifen because they considered it to be a
‘cancer drug’ that was inextricably linked with the disease and
their family’s history of using the drug [28]. Several trial-related
factors were barriers to enrolment including the time commit-
ment and the concept of randomization [25]. Altruism was a
motivating factor for some women [25, 79]. Factors mentioned
in only one study can be found in Table 6.
discussion
In this systematic review of studies investigating decision-
making in the context of breast cancer preventive therapy, we
observed low uptake of all agents and poor long-term persist-
ence. In our meta-analysis including over 21 000 women, only
one in six women decided to take preventive therapy or enter a
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Table 4. Summary of factors affecting adherence to breast cancer preventive therapy
Day et al.
[59]
Fallowfield
et al. [61]
Klepin
et al. [62]
Land
et al. [63]
Land
et al. [64]
Maurice
et al. [65]
Palva
et al. [67]
Powles
et al. [68]
Powles
et al. [69]
Powles
et al. [70]
Signori
et al. [71]
Clinical factors
Placebo versus tamoxifen
(tamoxifen lower)
✓ ✓✓ – ✓ ✓
Raloxifene versus
tamoxifen (tamoxifen lower)
✓✓ ✓ ✓
Higher objective risk ✓✓ –
Presence of diabetes –
Presence of heart disease –
Presence of impaired vision –
Less depression ✓ ✓ –
Diagnosis of prior
malignancy
–
Comorbid condition –
Taking other medications – ✓
Hysterectomy –
Menopausal status – –
Previous breast biopsy –
Patient factors
Longer expected time on
treatment
✓✓
Cognitive abilitya –
Alcohol consumption –
Non-smoker ✓✓ ✓
Overweight/obese –
Physical activity –
Demographic factors
Younger age ✓ ✓✓ –
Ethnicity – –
More education – ✓✓
Employment –
Income –
Living alone –
Marital status –
Parity –
Notes: –, tested, but not statistically significant;✓, tested in univariable analyses, and significant;✓✓, tested in multivariable analyses, and significant.
aKeplin et al. tested multiple different cognitive abilities and only verbal fluency (✓✓) and verbal fluency were significant (✓✓).
Table 5. Characteristics of qualitative studies discussing breast cancer preventive therapy decision-making
Study Country Design Analysis Setting Agent n Age, years (% of sample)
Altschuler and
Somkin [25]
USA Mixed Grounded theory STAR Tamoxifen; raloxifene 51 40–49 (2%); 50–59 (29%);
60–69 (35%); 70–79
(31%); >80 (2%)
Cyrus-David and
Strom [78]
USA Qualitative Cross-case analysis
using variable-oriented
strategies
Non-trial Tamoxifen; raloxifene 26 30–59 (54%); ≥60 (42%);
unknown (4%)
Donnelly et al. [28] UK Mixed Framework analysis Non-trial Tamoxifen 30 Median, 42
Heisey et al. [79] Canada Qualitative Framework analysis Non-trial; STAR Tamoxifen; raloxifene 27 Median, 61
Holmberg et al. [77] USA Qualitative Narrative theory STAR Tamoxifen 2 73 and 52
Paterniti et al. [80] USA Qualitative Unclear, likely to be
thematic
Non-trial Tamoxifen 27 68.3 years (61–78)
Salant et al. [81] USA Qualitative Grounded theory Non-trial Tamoxifen 33 Mean 55 (range, 33–70)
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Table 6. Qualitative themes affecting decision-making and uptake of preventive therapy
Risk Side-effects Knowledge Medication concerns Information Trial- issues Other
Altschuler and
Somkin [25]
Perceived personal risk; threat
of other disease
Side-effect
concerns
Concern about
contraindication of HRT
Altruism; time;
commitment;
randomization
Cyrus-David et al.
[78]
Accuracy of risk perceptions;
perceived wellness
Knowledge of risk
factors; awareness
of chemoprevention
Drug interactions; chemical
properties of drugs; length
of treatment
Patient–provider
communication
Distrust of medical system;
conception issues; cost
Donnelly et al. [28] Daily reminder of risk Side-effect
concerns
Tamoxifen as a ‘cancer drug’ Impact of others’ experience
Heisey et al. [79] Perceived personal risk; denial
of risk; expectations for
risk-reduction
Side-effect
concerns
Aversion to medication; HRT
controversies
Lack of information;
information sources
Altruism Being in control; term
‘chemoprevention’; cost
Holmberg et al. [77] The meaning of ‘risk’;
personalized risk
assessments; concern about
possible diagnosis;
comparisons with coronary
heart risk
Paterniti et al. [80] Perceived personal risk;
alternative approaches to
reducing risk
Risks and benefits of
tamoxifen
Meaning of breast cancer;
religiosity
Salant et al. [81] Perceived personal risk; lack
of symptoms/problems
Mythical causes of
breast cancer
Dislike of medication; use of
medication to treat rather
than prevent
Cognitive avoidance of cancer
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chemoprevention trial. We were unable to explain the heterogen-
eity observed in the model using pre-speciﬁed subgroup analyses
comparing agent, context and location. Short-term persistence
was high, and women demonstrated adequate use of medications
on a day-to-day basis. However, persistence with preventive
therapy for 5 years was low, limiting the preventive effect in these
women. These data suggest future research should be directed
towards supporting decision-making at the point of uptake, as
well as ensuring mechanisms are in place to promote persistence
among women who have initiated therapy.
Our estimate of uptake is comparable with a previous meta-
analysis reporting 15% of women accepted the offer of prevent-
ive therapy in ﬁve studies outside a trial setting [14]. However,
subgroup analysis suggested uptake in clinical settings was sig-
niﬁcantly lower than this estimate. The difference in uptake
between settings suggests issues with implementing preventive
therapy within routine patient care. Clinician’s attitudes towards
the topic of preventive therapy are not well known, but prescrib-
ing concerns may affect their willingness to discuss this option
[82]. For example, tamoxifen and raloxifene are not licensed for
prevention in some countries, which can dissuade prescribing
[82–84]. Discussing medication and writing prescriptions are
also unfamiliar tasks for many clinicians working with high-risk
populations. Providing appropriate support and training may
encourage the implementation of preventive therapy into routine
patient care.
There was considerable heterogeneity in our uptake estimate,
and this is likely to be a result of speciﬁc studies reporting high
enrolment rates. The highest uptake (54.9%) was reported in a
small (n = 51) mixed methods study, where interest may have
been higher because the study protocol involved attendance at
an interview [25]. Similarly, uptake in speciﬁc centres of the
IBIS-II trial was high, perhaps because enrolment was only dis-
cussed with women actively seeking information about the trial
[34]. Caution should therefore be taken when interpreting these
uptake data, as they may include populations who are more
interested in prevention than the general population. They also
only include women who have actively sought clinician advice
about their breast cancer risk. Other clinical groups such as
those with benign breast disease [85], dense breasts [13] and
older women may meet risk thresholds, but are not routinely
offered preventive therapy.
Efforts to support patient decision-making may be guided by
our attempt to identify the factors related to higher uptake and
adherence. Concerns about medication were important in both
quantitative and qualitative studies within this review. For
example, in a US study of 129 women with follow-up at 2 and 4
months after counselling, those who were more concerned
about side-effects or were unconvinced by tamoxifen’s prevent-
ive effect were less likely to initiate therapy [26]. Other concerns
included the perception that tamoxifen was a ‘cancer drug’ that
would serve as a reminder of family members who had used it
[28]. Mistrust of medication in general was also a common atti-
tude [79, 81]. These observations support a meta-analysis of the
Necessity Concerns Framework, which showed lower adherence
among patients who felt medication was an unnecessary part of
their disease management, or among those who expressed
greater concerns about the use of medication [86]. Attempts to
correct such beliefs have had mixed results [87–89], but several
studies have indicated that necessity beliefs and concerns are
amenable to change [90–92].
Data from our review suggest receipt of a clinician recommen-
dation may not be sufﬁcient to increase uptake [26, 36], but dis-
cussions about the risks and beneﬁts of preventive therapy are
necessary for informed decision-making [93]. Studies suggested
women making informed decisions were equally likely to initiate
therapy. One study reported higher uptake among patients who
believed that all their questions had been answered and that
their clinician had helped them understand [48]. A decision-aid
tested in the context of a clinical trial was also effective in support-
ing women’s decision-making, without reducing uptake [34].
There is a clear demand for information about preventive therapy
[79], and awareness levels are low [78]. Women’s decision-
making about preventive therapy could beneﬁt from patient-
centred communications, which outline the risks and beneﬁts of
preventive therapy in a comprehensible manner [94].
Studies comparing tamoxifen with placebo or raloxifene con-
sistently reported higher drop-out rates among the tamoxifen
arm, suggesting side-effects unique to the drug may be respon-
sible [61–64, 67, 69, 70]. Furthermore, several studies collecting
OTFs suggested over half of all drop-outs were a result of medi-
cation side-effects [59, 60, 63, 67–70]. Clinicians counselling
women with side-effects from tamoxifen could consider pre-
scribing more tolerable agents with similar effectiveness [75,
76]. While these data are somewhat useful in explaining low
long-term persistence, the method is likely to be prone to bias.
For example, women who had already chosen to cease participa-
tion may have been more likely to attribute their decision to a
medical factor, thereby exaggerating the importance of side-
effects. To resolve this issue, future studies are needed that
prospectively collect patient-reported outcome data to enable
comparisons between those who do and do not persist. In the
meantime, accurate side-effect data should be conveyed to
women who express concerns about safety [26, 51, 78, 79, 81].
Due to differences in the reporting and recording of adher-
ence, we were unable to synthesize the data in a meta-analysis.
Despite advantages and disadvantages to different methods,
there is currently no gold standard for deﬁning or measuring
adherence. This is a limitation in all settings in which medica-
tion is taken, and is not solely observed in oncology. Research is
needed that not only seeks ways to promote adherence to these
therapies, but more broadly can standardize the manner in
which this behaviour is quantitatively assessed to allow a better
comparison between studies. This would include agreed upon
means for classifying adherence, including evidence-based
thresholds for what can be considered adequate adherence. The
review was further limited by the low number of studies
included in countries outside of the USA and Europe. This
should be addressed in the light of the rising incidence rates in
developing countries [7]. There were also insufﬁcient reports of
agents other than SERMs. The ongoing evaluation of next-gen-
eration agents such as AIs should be accompanied by detailed
adherence reports.
conclusions
Preventive therapy uptake for the prevention of breast cancer is
low, and long-term persistence is often insufﬁcient for women
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to experience the full preventive effect. Uptake is higher in
trial settings, suggesting further work is needed to identify
the problems with implementing preventive therapy within
routine clinical practice. Improving the communication of in-
formation about preventive therapy is likely to beneﬁt women,
but further research should identify additional factors amend-
able to modiﬁcation to promote informed decisions related to
chemoprevention.
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